AIMC Topic: Adenocarcinoma of Lung

Clear Filters Showing 31 to 40 of 207 articles

MLG2Net: Molecular Global Graph Network for Drug Response Prediction in Lung Cancer Cell Lines.

Journal of medical systems
Drug response prediction (DRP) is a central task in the era of precision medicine. Over the past decade, the emergence of deep learning (DL) has greatly contributed to addressing DRP challenges. Notably, the prediction of DRP for cancer cell lines be...

A Novel Theranostic Strategy for Malignant Pulmonary Nodules by Targeted CECAM6 with Zr/I-Labeled Tinurilimab.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Lung adenocarcinoma (LUAD) constitutes a major cause of cancer-related fatalities worldwide. Early identification of malignant pulmonary nodules constitutes the most effective approach to reducing the mortality of LUAD. Despite the wide application o...

Analysis of Multiple Programmed Cell Death Patterns and Functional Validations of Apoptosis-Associated Genes in Lung Adenocarcinoma.

Annals of surgical oncology
BACKGROUND: Lung adenocarcinoma (LUAD) is marked by its considerable aggressiveness and pronounced heterogeneity. Programmed cell death (PCD) plays a pivotal role in the progression of tumors, their aggressive behavior, resistance to treatment, and r...

Development and validation of machine learning models for early diagnosis and prognosis of lung adenocarcinoma using miRNA expression profiles.

Cancer biomarkers : section A of Disease markers
ObjectiveStudy aims to develop diagnostic and prognostic models for lung adenocarcinoma (LUAD) using Machine learning(ML)algorithms, aiming to enhance clinical decision-making accuracy.MethodsData from The Cancer Genome Atlas (TCGA) for LUAD patients...

A CNN-transformer fusion network for predicting high-grade patterns in stage IA invasive lung adenocarcinoma.

Medical physics
BACKGROUND: Invasive lung adenocarcinoma (LUAD) with the high-grade patterns (HGPs) has the potential for rapid metastasis and frequent recurrence. Therefore, accurately predicting the presence of high-grade components is crucial for doctors to devel...

Predictive models of epidermal growth factor receptor mutation in lung adenocarcinoma using PET/CT-based radiomics features.

Medical physics
BACKGROUND: Lung adenocarcinoma (LAC) comprises a substantial subset of non-small cell lung cancer (NSCLC) diagnoses, where epidermal growth factor receptor (EGFR) mutations play a pivotal role as indicators for therapeutic intervention with targeted...

Preoperative Prediction of STAS Risk in Primary Lung Adenocarcinoma Using Machine Learning: An Interpretable Model with SHAP Analysis.

Academic radiology
BACKGROUND: Accurate preoperative prediction of spread through air spaces (STAS) in primary lung adenocarcinoma (LUAD) is critical for optimizing surgical strategies and improving patient outcomes.

A tumor-infiltrating B lymphocytes -related index based on machine-learning predicts prognosis and immunotherapy response in lung adenocarcinoma.

Frontiers in immunology
INTRODUCTION: Tumor-infiltrating B lymphocytes (TILBs) play a pivotal role in shaping the immune microenvironment of tumors (TIME) and in the progression of lung adenocarcinoma (LUAD). However, there remains a scarcity of research that has thoroughly...

Deep learning radiomics for the prediction of epidermal growth factor receptor mutation status based on MRI in brain metastasis from lung adenocarcinoma patients.

BMC cancer
BACKGROUND: Early and accurate identification of epidermal growth factor receptor (EGFR) mutation status in non-small cell lung cancer (NSCLC) patients with brain metastases is critical for guiding targeted therapy. This study aimed to develop a deep...

Prediction of tumor spread through air spaces with an automatic segmentation deep learning model in peripheral stage I lung adenocarcinoma.

Respiratory research
BACKGROUND: To evaluate the clinical applicability of deep learning (DL) models based on automatic segmentation in preoperatively predicting tumor spread through air spaces (STAS) in peripheral stage I lung adenocarcinoma (LUAD).